Contributions of this study include improving researchers' and clinicians' understanding of how genetic variation in the CES1 gene primarily responsible for the metabolism of methylphenidate impacts adverse events and dose requirements in children with ADHD. The gene discussed is CES1; the disease is attention deficit-hyperactivity disorder.